ring finger protein 17Genealiases: Mmip-2 · SPATA23 · TDRD4
Q-omics provides the consensus-scored RNF17 profile across patient tissues and cancer cell-line models. RNF17 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RNF17 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, RNF17 RNA expression shows 9,997 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, HNSC, and TGCT as cancer lineages where RNF17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF17 survival associations across molecular data types. RNF17 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF17 RNA expression–survival associations across cancer types. High RNF17 expression shows unfavorable associations in DLBC, LIHC, READ and COAD, but favorable associations in LUSC and ACC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify DLBC as the clearest survival context for RNF17 RNA expression.
This table summarizes RNF17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RNF17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF17 shows lower tumor expression in THCA and BRCA and higher tumor expression in HNSC, LIHC, LUSC and STAD. The HNSC box plot shows higher RNF17 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .009).
This table shows molecular features associated with RNF17 in patient tissues and cancer cell lines. In patient samples, RNF17 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OESOPHAGUS.
